Wang X, et al. - The safety, as well as effects of rituximab, were investigated in 36 non-responsive idiopathic membranous nephropathy (iMN) patients and it was found that in this patient population, rituximab therapy could induce remission of proteinuria and stabilization of renal function, even in those with damaged renal function. For individualized rituximab dosage and treatment monitoring, anti-phospholipase 2 receptor (PLA2R) antibodies may be used as a marker.